An Indian pharma professional analyzes trade data amidst medications and reports.
India is expected to be largely shielded from the impact of new US tariffs on patented drugs, according to a report by the Global Trade Research Initiative (GTRI). The tariffs are unlikely to have a significant impact because India primarily exports affordable generic medicines to the United States, which are currently exempt from these tariffs.
The GTRI report indicates that while the broad impact may be limited, Indian firms that produce specialized drugs or inputs for patented medicines could face some pressure. These companies may need to adjust their strategies to mitigate potential negative effects.
The report also notes that there is future uncertainty if the tariffs are extended to include generic medicines. Such a move could have a more substantial impact on Indian pharmaceutical exports. Stakeholders are closely monitoring policy developments to assess potential risks and opportunities.
About the Author
